Skip to main content
Vercise Genus R32 and R16 rechargeable batteries.

Vercise Genus™ Rechargeable Batteries

Therapy Without Compromise

Proven battery technology

10 years on the market and more than 25,000 patients1 implanted, Boston Scientific has a battery you can depend on.

  • Pioneers in Multiple Independent Current Control (MICC)
  • 200 mAh battery
  • 15-year limited warranty
  • Access to MRI Imaging2
  • Bluetooth© capable

The most therapy options*

No two deep brain stimulation (DBS) patients are alike.
The Vercise Genus DBS Systems give you the most therapy options available to offer your patients the personalized DBS therapy they deserve.

  • Up to 33 independently powered contacts
  • Directional bipolar stimulation
  • Anodic stimulation
  • Multipolar stimulation
  • Multiple frequencies
  • Stim-on steering

30 days of recharge-free therapy

The Boston Scientific Vercise™ DBS Rechargeable Batteries offer patients easy recharging to match their lifestyle. At typical clinical settings, Boston Scientific Vercise DBS Rechargeable Batteries provide 30 days of stimulation between recharging cycles.3

Vercise Genus R32 and R16 batteries.

Real patients share the charging routine that works best for them**

— Peter V., Implanted 2012

“When I was first implanted, I was recharging once every two weeks. It has been 6 years since my surgery, and today I am recharging once every two weeks.”

— Lisa G., Implanted April 2019

“5 minutes [of charging] … twice a week at most. It’s simple as pie.”

Hear from our ambassadors in their own words

Patients can charge in 3 easy steps

1. Charge the Charger

2. Place the Charger within the Charging Collar

3. Position the Collar to align the Charger

Using Your Vercise DBS Charging System: A Quick Start Guide for Patients and Caregivers. Boston Scientific. 92354415-01.
Not meant as a replacement for the Vercise™ DBS Charger Handbook. All information from the Handbook should be well understood before using the charger.

Still not sure your patient is the right fit for a rechargeable battery?
We have options

If your patients prefer a battery that doesn't require charging, the Vercise Genus non-rechargeable batteries feature the same advanced therapy options as the rechargeable batteries.

*Information for competitive devices excerpted from the literature published by Medtronic (M982261A015 Rev A, M017563C002 Rev A, M939241A051 Rev A, M927170A073 Rev A, M017562C002 Rev A) and Abbott (ARTEN600150429 - B, ARTEN600102238 - A), and
Schüpbach, Michael & Chabardes, Stephan & Matthies, Cordula & Pollo, Claudio & Steigerwald, Frank & Timmermann, Lars & Vandewalle, Veerle & Volkmann, Jens & Schuurman, P.. (2017). Directional leads for deep brain stimulation: Opportunities and challenges. Movement Disorders. 32. 10.1002/mds.27096.
Steffen, J. K., Reker, P., Mennicken, F. K., Dembek, T. A., Dafsari, H. S., Fink, G. R., Visser-Vandewalle, V., & Barbe, M. T. (2020). Bipolar Directional Deep Brain Stimulation in Essential and Parkinsonian Tremor. Neuromodulation: Technology at the Neural Interface, 23(4), 543–549. DOI: 10.1111/ner.13109
Reker, P., Dembek, T. A., Becker, J., Visser-Vandewalle, V., & Timmermann, L. (2016). Directional deep brain stimulation: A case of avoiding dysarthria with bipolar directional current steering. Parkinsonism & Related Disorders, 31, 156-158.
Kirsch, A. D., Hassin-Baer, S., Matthies, C., Volkmann, J., & Steigerwald, F. (2018). Anodic versus cathodic neurostimulation of the subthalamic nucleus: A randomized-controlled study of acute clinical effects. Parkinsonism & Related Disorders, 55, 61-67.
Boston Scientific (Vercise ™ Neural Navigator 5 Software Programming Manual MP92736308-01).

**The patient quotes describe real personal experiences. Individual results may vary. Consult with your physician to determine if you are a candidate for this procedure and what you may gain from the therapy.

The Bluetooth® word mark and logos are registered trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Boston Scientific Neuromodulation Corporation is under license.

1. Boston Scientific data on file.

2. For complete instructions on MRI for labeling and safety conditions, refer to ImageReady™ MRI guidelines for Boston Scientific.

3. Yu et al. (2013). “Characterizing Rechargeable IPG Charge Cycle Time in DBS.” NANS 2013 Poster.

Indication for Use: The Boston Scientific Vercise™ PC, Vercise Gevia™, Vercise Genus™ Deep Brain Stimulation Systems are indicated for use in:

  • Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
  • Bilateral stimulation of the internal globus pallidus (GPi) as an adjunctive therapy in reducing some of the symptoms of advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
  • Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability.

The Boston Scientific Vercise Deep Brain Stimulation System is indicated for use in:

  • Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.

Contraindications, warnings, precautions, side effects: The Boston Scientific Deep Brain Stimulation (DBS) Systems or any of its components, are contraindicated for: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) as the safety of these therapies in patients implanted with the Boston Scientific DBS System has not been established, patients who are unable to operate the system, patients who are poor surgical candidates or who experience unsuccessful test stimulation. Patients implanted with Boston Scientific DBS System without ImageReady™ MRI Technology should not be exposed to Magnetic Resonance Imaging (MRI). Patients implanted with Vercise Gevia or Vercise Genus or Vercise Genus Mixed System with M8 Adapter or Vercise DBS Lead-Only System (before Stimulator is implanted) with ImageReady MRI Technology are Full Body MR Conditional only when exposed to the MRI environment under the specific conditions defined in ImageReady MRI Guidelines for Boston Scientific DBS Systems. Assess patients for the risks of depression and suicide. This assessment should consider both the risk of depression and suicide as well as the potential clinical benefits of DBS therapy. Monitor patients for new or worsening symptoms of depression, suicidal thoughts or behaviors, or changes in mood or impulse control and manage appropriately.  Refer to the Instructions for Use provided with the Boston Scientific DBS Systems or for potential adverse effects, warnings, and precautions prior to using this product. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.